Sialic Acid Conjugate-Modified Cationic Liposomal Paclitaxel for Targeted Therapy of Lung Metastasis in Breast Cancer: What a Difference the Cation Content Makes-百迪生物科技

首页 > 文献支持 > Sialic Acid Conjugate-Modified Cationic Liposomal Paclitaxel for Targeted Therapy of Lung Metastasis in Breast Cancer: What a Difference the Cation Content Makes

Sialic Acid Conjugate-Modified Cationic Liposomal Paclitaxel for Targeted Therapy of Lung Metastasis in Breast Cancer: What a Difference the Cation Content Makes

2024-02-26·文献支持

加入收藏去分享

发布日期：1708905600

来源：DOI〖10.1021/acs.molpharmaceut.3c00767〗

作者：Wenliang Sun, Chao Han, Ruirui Ge, Xiaotong Jiang, Yu Wang, Yingchao Han, Ning Wang, Yanzhi Song

加入收藏去分享

来源网址：https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.3c00767

期刊：Molecular pharmaceutics 丨丨引用百迪产品：L100-500（DMEM高糖培养基，含丙酮酸钠，含谷氨酰胺）

IF：4.9

日期：2024-03-01

Human papillomavirus-16 E6 activates the pentose phosphate pathway to promote cervical cancer cell proliferation by inhibiting G6PD lactylation

日期：2024-02-23

Sorafenib-Encapsulated Liposomes to Activate Hypoxia-Sensitive Tirapazamine for Synergistic Chemotherapy of Hepatocellular Carcinoma

解决方案

关于百迪